Insights Center
ML Strategies Viewpoints
Search
Showing 41 - 48 of 493 results
New Medicare Advantage and Part D Drug Pricing Proposed Rule
December 5, 2018|Blog
ML Strategies 2018 Outlook: Education
December 5, 2018|Advisory
ML Strategies Outlook for 2018
December 5, 2018|Advisory
Overview of the Virginia 1115 Medicaid Waiver Application
December 4, 2018|Blog
ML Strategies Health Care Preview - Week of December 3rd
December 3, 2018|Blog
Looking Ahead to 2019 and the New 116th Congress
December 3, 2018|Advisory
Overview of CMS' 1332 Waiver Concepts
November 30, 2018|Blog
115th Congress Nears End: What’s Left on the Lame Duck Agenda?
November 28, 2018|Advisory
News & Press Releases
To Pitch Pre-Cert to Congress, FDA Builds a Case First
September 26, 2019 | MedTechDive
MedTechDive reported that the U.S. Food and Drug Administration is not yet ready to go to Congress to seek new powers for its evolving precertification pilot for software, but it will need new authorities to determine how the experimental path fits into the current regulatory scheme. The article included commentary from Senior Director of ML Strategies Aaron Josephson and Mintz Associate Benjamin Zegarelli.
Former FDAer Defends FDA Decision to Withdraw Data Falsification Rule
August 20, 2019 | Inside Health Policy
An article published by Inside Health Policy quoted Aaron Josephson, Senior Director at ML Strategies, extensively in response to recent debate surrounding the U.S. Food and Drug Administration’s proposed rule “Reporting Information Regarding Falsification of Data,” which was previously withdrawn.
Events
Nov
8
2019